Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
| ▸ | TACR2 | P21452 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941176 | 0.90 | KDM4E (0.43) | KMT2ATACR2SLC6A2SLC6A4KDM4E | |
| SCHEMBL4942393 | 0.85 | P2RX7 (0.39) | TACR2SLC6A2SLC6A4 | |
| SCHEMBL6949126 | 0.84 | KMT2A (0.46) | KMT2ATACR2TACR1SLC6A2SLC6A4 | |
| SCHEMBL6661492 | 0.83 | KMT2A (0.45) | KMT2ATACR2TACR1SLC6A2SLC6A4 | |
| SCHEMBL6663095 | 0.83 | KMT2A (0.45) | KMT2ATACR2TACR1SLC6A2SLC6A4 | |
| SCHEMBL14028100 | 0.82 | SLC6A4 (0.42) | KMT2ASLC6A2SLC6A4 | |
| SCHEMBL6952753 | 0.81 | KMT2A (0.43) | KMT2ATACR1SLC6A2SLC6A4 | |
| SCHEMBL4941557 | 0.81 | TACR2 (0.39) | KMT2ATACR3TACR2TACR1CNR2 | |
| SCHEMBL6192006 | 0.80 | KMT2A (0.41) | KMT2ATACR3TACR2TACR1CNR2 | |
| SCHEMBL6948569 | 0.80 | KMT2A (0.43) | KMT2ATACR2TACR1SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261976-A1 | NOVEL PIPERIDINECARBOXAMIDE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI-AVENTIS (FR) | 2008-10-23 | — | — | US | disclosed |
| EP-1395582-B1 | NOVEL PIPERIDINECARBOXAMIDE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI AVENTIS (FR) | 2005-05-04 | — | — | EP | disclosed |
| US-20040180890-A1 | Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | US | disclosed |
| EP-1395582-A1 | NOVEL PIPERIDINECARBOXAMIDE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Sanofi-Aventis (FR) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002094821-A1 | NOVEL PIPERIDINECARBOXAMIDE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI-SYNTHELABO (FR) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261976-A1 | NOVEL PIPERIDINECARBOXAMIDE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | TACR2, TACR1, KIT | KMT2A 674/4885TACR3 73/4885TACR2 1/4885 |
| US-20040180890-A1 | Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same | KIT, TACR2, P2RX3 | KMT2A 532/4885TACR3 80/4885TACR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.